Elevate-Derm Summer 2026 faculty share practical lessons on hair loss exams, PIH, geriatric dermatology, and managing cholesterol rises on JAK inhibitors.
|Articles|July 3, 2023
POLL: Do Your Treat Burns in Your Practice/Clinic?
Author(s)Dermatology Times Staff
Listen
0:00 / 0:00
Key Takeaways
- The 4th of July increases burn risks from fireworks, firepits, and grilling, impacting dermatology providers' treatment decisions.
- Dermatologists must decide whether to treat burns or refer patients to specialized care, considering their expertise and resources.
Click here to answer this week's poll.
Advertisement
As the 4th of July approaches, the risk of accidental burns increases with fireworks, firepits, and outdoor grilling. We want to know, as a dermatology provider, do you treat burns, or do you refer patients elsewhere?
Do you treat burns in your practice/clinic?
If you have additional thoughts about the dermatologist's or advanced practice provider's role in burn care, email us at
Advertisement
Related to this article
Atopic dermatitis care is evolving with flexible biologic dosing, expanded pediatric options, and novel oral, topical, and systemic therapies.
Updated SKYRIZI labeling allows clinicians to use clinical judgment when determining the need for TB evaluation before treatment.
Experts outline how to recognize undertreated psoriasis, assess incomplete response, and make individualized decisions when escalating therapy.
ATI-052 improved disease severity and itch in a phase 1b trial of patients with severe atopic dermatitis, with no grade 3 or 4 adverse events.
LRM will evaluate injectable rhPDGF-BB as a regenerative approach to infraorbital hollowing in a randomized phase 2b trial.
ORKA-001 achieved PASI 100 in 61% of high-dose patients at week 16 in the phase 2b EVERLAST-B trial of moderate-to-severe psoriasis.
Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Revises TB Evaluation Guidance for SKYRIZI
2
Biologics, JAK Inhibitors, and Atopic March Data in Pediatric Atopic Dermatitis
3
ATI-052 Shows Rapid Improvements in Atopic Dermatitis
4
How Approvals, Setbacks, and a Crowded Pipeline Are Reshaping the AD Treatment Landscape
5